199192-04-6

Basic information

• Product Name: 1H-Imidazole-4-carboxaldehyde,1-propyl-(9CI)
• Synonyms: 1H-Imidazole-4-carboxaldehyde,1-propyl-(9CI);1-Propyl-1H-iMidazole-4-carbaldehyde;1-propyl-1H-Imidazole-4-carboxaldehyde;1-PROPYL-1H-IMIDAZOLE-4-CARBALDEHYDE(WXG01740)
• CAS NO: 199192-04-6
• Molecular Formula: C₇H₁₀N₂O
• Molecular Weight: 138.1671
• Product Categories: AMINETERTIARY
• Mol File: 199192-04-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1H-Imidazole-4-carboxaldehyde,1-propyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazole-4-carboxaldehyde,1-propyl-(9CI)(199192-04-6)
• EPA Substance Registry System: 1H-Imidazole-4-carboxaldehyde,1-propyl-(9CI)(199192-04-6)

Safety Data

• Hazardous Substances Data: 199192-04-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-Imidazole-4-carboxaldehyde,1-propyl-(9CI) is utilized as a synthetic intermediate for the creation of various organic compounds. Its unique structure allows for the formation of new molecules with potential applications across different industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1H-Imidazole-4-carboxaldehyde,1-propyl-(9CI) serves as a key component in the development of novel drugs. Its incorporation into molecular structures can lead to the discovery of new therapeutic agents with enhanced biological activity.
Used in Chemical Research:
1H-Imidazole-4-carboxaldehyde,1-propyl-(9CI) is also employed in chemical research to study the properties and reactions of imidazole derivatives. This can contribute to a deeper understanding of the chemistry involved and facilitate the design of new chemical processes and applications.

Upstream product

• 106-94-5 propyl bromide 
• 3034-50-2 4⁽⁵⁾formylimidazole 
• 109-65-9 1-bromo-butane 
• 107-08-4 1-iodo-propane 
• 199191-93-0 1-(3-bromopropyl)-1H-4-imidazolecarbaldehyde 

Downstream Products

• 570398-27-5 2-[Hydroxy(1-propyl-1H-imidazol-4-yl)methyl]-4-(4-methoxybenzyl)-3-morpholinone 
• 497853-49-3 7-{4-[2-(butoxy)ethoxy]phenyl}-1-isobutyl-N-({4-[(1-propyl-1H-imidazol-4-yl)methyl]sulfanyl}phenyl)-2,3-dihydro-1H-1-benzazepine-4-carboxamide 
• 343269-72-7 (1-propyl-1H-imidazol-4-yl)methanol 

Relevant articles and documents

Identification of novel imidazole flavonoids as potent and selective inhibitors of protein tyrosine phosphatase

A series of imidazole flavonoids as new type of protein tyrosine phosphatase inhibitors were synthesized and characterized. Most of them gave potent protein phosphatase 1B (PTP1B) inhibitory activities. Especially, compound 11a could effectively inhibit P

Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis

Thrombin-activatable fibrinolysis inhibitor (TAFI) has emerged as a key link between the coagulation and fibrinolysis cascades and represents a promising new target for the treatment of thrombosis. A novel series of imidazolepropionic acids has been designed that exhibit high potency against activated TAFI (TAFIa) and excellent selectivity over plasma carboxypeptidase N (CPN). Structure activity relationships suggest that the imidazole moiety plays a key role in binding to the catalytic zinc of TAFIa, and this has been supported by crystallographic studies using porcine pancreatic carboxypeptidase B as a surrogate for TAFIa. The SAR program led to the identification of 21 (TAFIa Ki = 10 nM, selectivity TAFIa/CPN > 1000) as a candidate for clinical development. Compound 21 exhibited antithrombotic efficacy in a rabbit model of venous thrombosis, yet had no effect on surgical bleeding in the rabbit. In addition, 21 exhibited an excellent preclinical and clinical pharmacokinetic profile, characterized by paracellular absorption, low clearance, and a low volume of distribution, fully consistent with its physicochemical properties of low molecular weight (MW = 239) and high hydrophilicity (log D = -2.8). These data indicate 21 (UK-396,082) has potential as a novel TAFIa inhibitor for the treatment of thrombosis and other fibrin-dependent diseases in humans.

Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety

In order to develop orally active CCR5 antagonists, 1-propyl- or 1-isobutyl-1-benzazepine derivatives containing a sulfoxide moiety have been designed, synthesized, and evaluated for their biological activities. Sulfoxide compounds containing a 2-pyridyl

BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE

The present invention provides a novel benzazepine derivative represented by formula : wherein, R1 is a 5- or 6-membered aromatic ring, R2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula -W1-X2-W2- (W1 and W2 are independently S(O)m1 (m1 is 0, 1 or 2), etc., and X2 is an optionally substituted alkylene groupetc. ), a preparation method and use thereof.

3-(Imidazolyl)-2-alkoxypropanoic acids

Compounds according to formula (I) wherein n is 0-3, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and optionally substituted C1-6 alkyl, or R5 and R8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.

Pharmaceuticals

The present invention provides compounds of formula (I) as well as the use of such compounds in pharmaceutical compositions and methods of treatment. The compounds described herein represent a class of TAFIla inhibitors suitable for use in treating condit

Bu3SnH mediated oxidative radical cyclisation onto imidazoles and pyrroles

A new protocol using radical cyclisation has been developed for the synthesis of [1,2-c]-fused imidazoles and [1,2-a]-fused pyrroles. The intermediate nucleophilic N-alkyl radicals, generated using Bu3SnH from N- (ω-bromoalkyl) or N-[ω-(phenylselanyl)alkyl] imidazoles and pyrroles, undergo regio-selective radical cyclisalion onto the azole rings followed by oxidative re-aromatisation.

Oxidative radical cyclisations onto imidazoles and pyrroles using Bu3SnH

Oxidative radical cyclisation using Bu3SnH has been used for the synthesis of [1,2-c]-fused imidazoles and [1,2-a]-fused pyrroles from imidazolecarbaldehydes and acylpyrroles respectively. The intermediate nucleophilic N-alkyl radicals cyclise onto imidazole and pyrrole rings followed by oxidative re-aromatisation.